HMOX1 and breast cancer: Thus, TAMs’ HO-1 inhibition in the context of BC therapy could potentially lead to improved treatment outcomes by enhancing the effectiveness of chemotherapy and inhibiting tumor progression through HO-1-targeted reprogramming toward the M1 phenotype [192].